The long-term trend of the EPS is a vital number as it helps understand the future potential of Akers Biosciences Inc. It is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -78.90 % over the last twelve months. Growth in EPS is an important measure of administration performance because it shows how much money Akers Biosciences Inc is making for it’s investors or shareholders.

Akers Biosciences Inc is in the medical instruments and equipment industry and is in the healthcare sector. The company CEO is Howard R. Yeaton. Akers Biosciences Inc mainly develops and manufactures rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner.

Previous Intraday Performance:

The AKER shares had a previous change of -8.49% which opened at 1.63 and closed at 1.51. It moved to an intraday high of 1.65 and a low of 1.48.

SeekingAlpha:  Thin ranks in premarket gainers

Historical Performance:

Over the last five trading days, AKER shares returned -11.70% and in the past 30 trading days it returned -47.57%. Over three months, it changed -24.98%. In one year it has changed -61.07% and within that year its 52-week high was 7.84 and its 52-week low was 0.98. AKER stock is 54.71% above its 52 Week Low.

Our calculations result in a 200 day moving average of 3.39 and a 50 day moving average of 2.51. Right now, AKER stock is trading -55.50% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Thin ranks in premarket gainers


The company has a market cap of $18.8m with 12.5m shares outstanding and a float of 11.6m shares. Trading volume was 392,530 shares and has experienced an average volume of 1,257,881 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Akers Biosciences Inc was -6.32 which ended on 31st of December 2017.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.26
06-30-2018:  -0.02
03-31-2018:  -0.03
12-31-2017:  -0.23

Indicators Also to Watch:

Based on the latest filings, there is 1.00% of insider ownership and 110.20% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.

I calculated the beta to be -101.46

PR Newswire:  Bancorp 34, Inc. Announces Adoption Of Repurchase Program

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -162.39%, return on assets is -121.83%, price-to-sales is 7.32 and price-to-book is 2.44.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here